Evofem Biosciences Inc (EVFM) Expected to Announce Earnings of -$0.45 Per Share

Share on StockTwits

Brokerages expect Evofem Biosciences Inc (NASDAQ:EVFM) to post ($0.45) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evofem Biosciences’ earnings, with estimates ranging from ($0.53) to ($0.39). Evofem Biosciences posted earnings per share of ($4.62) during the same quarter last year, which indicates a positive year over year growth rate of 90.3%. The company is expected to report its next quarterly earnings results on Monday, May 13th.

On average, analysts expect that Evofem Biosciences will report full year earnings of ($1.32) per share for the current year, with EPS estimates ranging from ($1.72) to ($0.20). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.17) per share, with EPS estimates ranging from ($1.39) to ($0.87). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Evofem Biosciences.

Evofem Biosciences (NASDAQ:EVFM) last issued its quarterly earnings results on Friday, March 1st. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.15).

A number of research firms recently issued reports on EVFM. Cantor Fitzgerald reissued a “buy” rating and set a $9.00 price objective on shares of Evofem Biosciences in a research report on Monday, December 17th. HC Wainwright set a $11.00 price objective on Evofem Biosciences and gave the company a “buy” rating in a research report on Monday, December 10th. Oppenheimer set a $9.00 price objective on Evofem Biosciences and gave the company a “buy” rating in a research report on Monday, December 17th. ValuEngine cut Evofem Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Zacks Investment Research cut Evofem Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $10.70.

In other news, major shareholder Ltd. Invesco acquired 425,531 shares of Evofem Biosciences stock in a transaction that occurred on Friday, February 8th. The stock was purchased at an average price of $2.64 per share, with a total value of $1,123,401.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVFM. Heartland Advisors Inc. acquired a new stake in Evofem Biosciences during the third quarter valued at $1,319,000. Vanguard Group Inc. acquired a new stake in shares of Evofem Biosciences in the third quarter worth about $879,000. Vanguard Group Inc acquired a new stake in shares of Evofem Biosciences in the third quarter worth about $879,000. Finally, Geode Capital Management LLC lifted its position in shares of Evofem Biosciences by 115.2% in the fourth quarter. Geode Capital Management LLC now owns 73,650 shares of the biotechnology company’s stock worth $308,000 after buying an additional 39,425 shares during the last quarter. 79.56% of the stock is owned by hedge funds and other institutional investors.

Shares of EVFM stock traded down $0.09 on Monday, reaching $3.66. 7,235 shares of the company’s stock traded hands, compared to its average volume of 25,231. Evofem Biosciences has a 12-month low of $1.79 and a 12-month high of $8.50. The company has a market capitalization of $102.77 million, a price-to-earnings ratio of -0.64 and a beta of 1.62.

About Evofem Biosciences

Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.

Featured Story: Buy-Side Analysts

Get a free copy of the Zacks research report on Evofem Biosciences (EVFM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SPDR Portfolio Small Cap ETF  Stake Lessened by Asset Dedication LLC
SPDR Portfolio Small Cap ETF Stake Lessened by Asset Dedication LLC
Vermont utility Needs renewable power that is 100% by 2030
Vermont utility Needs renewable power that is 100% by 2030
Asset Dedication LLC Purchases 116 Shares of Adobe Inc
Asset Dedication LLC Purchases 116 Shares of Adobe Inc
American Century Companies Inc. Has $267,000 Stake in CoreSite Realty Corp
American Century Companies Inc. Has $267,000 Stake in CoreSite Realty Corp
American Century Companies Inc. Sells 1,516,500 Shares of Iamgold Corp
American Century Companies Inc. Sells 1,516,500 Shares of Iamgold Corp
iShares MSCI ACWI ETF  Position Lifted by American Century Companies Inc.
iShares MSCI ACWI ETF Position Lifted by American Century Companies Inc.


 
© 2006-2019 Zolmax.